# Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

> **NCT00350272** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 76 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Elvucitabine
- **DRUG:** Lamivudine
- **DRUG:** Tenofovir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00350272
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-08
- **Final completion:** 2009-04
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350272, "Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00350272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*